VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience
Kazuyoshi� Ishii(Kochi Medical School Hospital), Shosaku� Nomura(Kansai Medical University), Machiko Tsukaguchi(Sakai Municipal Hospital), Atsuko Mugitani(Fuchu Hospital), Masaru Shibano(Sakai Municipal Hospital), Hirofumi Teshima(Osaka City General Hospital), Fumiaki Urase(Kindai University Sakai Hospital), Masahiro Manabe(Osaka City General Hospital), Kunio Hayashi(Hoshigaoka Medical Center), Hidetsugu Kimura(Kindai University Sakai Hospital), Toshiya Yagi(Osaka City General Hospital), Yasuaki Nagare(Kindai University Sakai Hospital), Hitoshi Kitayama(Fukushima Medical University), Tatsuya Katsurada(Ijinkai Takeda General Hospital)
Cited by 7
Related Papers
The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis
|Cell|2001|715
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK
|Proceedings of the National Academy of Sciences|1998|492
Functional genomics reveals genes involved in protein secretion and Golgi organization
|Nature|2006|387
Identification of Rap1 as a Target for the Crk SH3 Domain-Binding Guanine Nucleotide-Releasing Factor C3G
|Molecular and Cellular Biology|1995|362